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Abstract 
 
This poster will describe a novel polymer pro-drug platform designed for conjugation and 
delivery of chemotherapeutics.  Specifically, polymer pro-drugs were prepared from 
functional polymer zwitterions and doxorubicin (DOX), and evaluated in vivo to assess 
toxicological, pharmacokinetic and therapeutic properties.  The biocompatible polymer 
scaffold (PolyMPC) consists of zwitterionic phosphorylcholine pendent groups, which 
mimic the natural hydrophilic moieties of phospholipids in cell membranes, and 
hydrazone linkages that allow for pH-triggered release of DOX.  PolyMPC-DOX pro-
drugs were isolated as dry solids using a facile strategy that allows for precise control of 
molecular weight and DOX incorporation.  In vivo toxicity of PolyMPC and PolyMPC-
DOX was assessed in a murine model.  The maximum tolerated dose of the pro-drug 
was five times greater than that of free DOX, while PolyMPC alone exhibited no toxicity 
even at a dose of 800 mg/kg.  A pharmacokinetic study in tumor-bearing mice 
demonstrated a significant increase in circulation half-life of conjugated DOX (t1/2=2 
hours) compared to free DOX (t1/2=15 minutes), with conjugated DOX detectable in 
blood serum for longer than 24 hours.  This pronounced enhancement in circulation time 
was attributed to the macromolecular scaffold, which precludes rapid renal clearance 
compared to native DOX.  Examination of mice given PolyMPC-DOX five days after 
injection in the PK study showed a three-fold increase of drug accumulated in tumor 
tissue compared to that of mice treated with free DOX and drug accumulation in off-
target organs was reduced for mice given DOX conjugate.  The therapeutic efficacy of 
the PolyMPC-DOX conjugates was then assessed in an orthotopic murine breast cancer 
model.  The treatment group given PolyMPC-DOX exhibited a two-fold increase in 
overall survival and a significant reduction in average tumor volume compared to the 
free DOX and saline control groups.  A study evaluating the therapeutic efficacy of 
PolyMPC-DOX in a human ovarian xenograft tumor model is ongoing.     
